Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial - Wikidata - wikimedia - TriplyDB

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

http://www.wikidata.org/entity/Q28036747

about

Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for advanced and/or metastatic colorectal cancer Sequential versus combination chemotherapy for advanced colorectal cancer Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for advanced and/or metastatic colorectal cancer Anti-angiogenic therapies for metastatic colorectal cancer Chemotherapy with Camptothecin compounds for metastatic colorectal cancer Anti-angiogenic therapy for metastatic colorectal cancer Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies Fully human IgG and IgM antibodies directed against the carcinoembryonic antigen (CEA) Gold 4 epitope and designed for radioimmunotherapy (RIT) of colorectal cancers Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer.Image-guided high-dose-rate brachytherapy of malignancies in various inner organs - technique, indications, and perspectives Molecular testing to optimize therapeutic decision making in advanced colorectal cancer Advances in targeted and immunobased therapies for colorectal cancer in the genomic era Evidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases.Pharmacologic resistance in colorectal cancer: a review Multimodality treatment strategies have changed prognosis of peritoneal metastases Mass Spectrometry-Based N-Glycomics of Colorectal Cancer Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer Monitoring of anti-cancer treatment with (18)F-FDG and (18)F-FLT PET: a comprehensive review of pre-clinical studies Precision medicine in colorectal cancer: the molecular profile alters treatment strategies Management of colorectal cancer FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy Imaging of complications of oncological therapy in the gastrointestinal system Development of a research agenda for the management of metastatic colorectal cancer: proceedings from a multidisciplinary research consensus panel Review of systemic therapies for locally advanced and metastatic rectal cancer Management of locally advanced and metastatic colon cancer in elderly patients Identification of clinically relevant molecular subtypes in colorectal cancer: the dawning of a new era UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy Role of Akt signaling in resistance to DNA-targeted therapy Unresolved issues and controversies surrounding the management of colorectal cancer liver metastasis Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer

P2860

Q24186145-31015811-78A5-41D7-B109-9410BEA6E478 Q24200737-9745FB67-4508-4BEB-AEF8-8C5B591DE817 Q24234461-6CE7CAAA-E197-47A4-8890-1507A2D7BBEB Q24234555-15C8376A-3827-44AD-8D2C-764B270C4B62 Q24241813-F8C1461E-5ED5-4850-A9BF-55A37C31032B Q24242475-F0600E87-E942-4F91-99C1-B9C73B13634A Q24243297-431B5A18-D3FF-4982-B303-B9D39C0D9D84 Q24646343-ECAE0660-F9A3-4494-9DFD-832C24C75CC7 Q24648015-F1AE6AEB-9EBD-4F69-B9F5-3A67C45BA748 Q24651894-DDDE4EE6-3AED-4FCF-A8D3-4E282FE71501 Q24792155-57199424-DF1F-4E3F-97C5-254320D60B83 Q24792609-FA4F01B4-A9B8-43EC-8F10-675415D6BEE2 Q24795149-96579B47-9DA2-41B0-8010-EDD9342F48E2 Q24795784-DB9AC720-39D7-4A1A-B08E-47D32C300E06 Q24801466-4C1BD7C5-C5F6-46E3-A124-920920B595D4 Q24806443-68723B19-A2BE-46C1-8504-1B58AE7F30B0 Q25256709-9D2BCC06-95DD-49A7-B2FE-BB892B5160D5 Q26738434-3BEB981B-7F90-481D-B664-21C11C823027 Q26749012-73E7FCC6-C874-4B0B-AB3B-8F85A68D9E0E Q26751344-2CBEB607-58EE-428E-BBFE-83D939850D9A Q26752747-7BAFD99A-5FC3-4094-B770-8A29588078D9 Q26769850-9BB6DFF0-7FF4-4519-80A6-8DBE6F0ED690 Q26769938-5E55CD20-F4D4-4EB2-884E-AEF2779109FD Q26774414-8A50E9B5-00B6-4ADE-9683-683B563ACE56 Q26774704-F9CC2395-91C7-4192-AAE3-6124BFCFF977 Q26775949-9166D764-9F01-4E7B-9F64-6A6ADC5646BE Q26778463-C8C2CE0D-BE23-4F97-AC16-18E8FF22A24E Q26795558-5EF73212-EC12-490E-ADA5-2BFFF5872D19 Q26823550-67C2FCF9-7DB3-4CD8-AAA8-B1C3F7DFA6CC Q26851060-C670B3FA-25FA-43A9-9A35-D366324C5FA8 Q27004641-A42BDB52-85A3-453C-9A96-8885C8E069E9 Q27014926-73D9A985-C8A5-458E-A3CC-63CF0A0DA995 Q27021105-F888A6A9-4F20-4BEA-8367-84A16E6629A0 Q27026129-D0901578-9DBD-4608-9E0E-6DB37D42C292 Q27693248-EAB9C5B4-DD60-4009-A55B-C957ED1A3953 Q27851574-58DEF2A0-49E3-48A2-A6AB-4A84533FC511 Q28066950-2D6E3B36-AD6B-4C2F-948C-2DD7F2CEA58E Q28085651-EC5BA2C9-136E-4F76-AAF2-15A735130717 Q28211801-3EB1E60A-D076-4B7C-A21F-E3BE9F73F246 Q28252635-90A3B23D-2F4D-4EC1-8922-F34CDA29D203

P2860

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

http://www.wikidata.org/entity/Q28036747

description

2000 nî lūn-bûn

@nan

2000 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի մարտին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Irinotecan combined with fluor ...... a multicentre randomised trial

@ast

Irinotecan combined with fluor ...... a multicentre randomised trial

@en

type

label

Irinotecan combined with fluor ...... a multicentre randomised trial

@ast

Irinotecan combined with fluor ...... a multicentre randomised trial

@en

prefLabel

Irinotecan combined with fluor ...... a multicentre randomised trial

@ast

Irinotecan combined with fluor ...... a multicentre randomised trial

@en

P1433

Q28036747-EEDC7086-3944-4154-B754-6B6356F51B90

P1476

Q28036747-50572E2F-C890-4D17-9E49-5CB69A07246E

P2093

Q28036747-090304AF-0C29-45E5-888E-1EAE74B7FD96

Q28036747-0D6D17E5-5491-49E6-99AF-492357855426

Q28036747-15001B9A-2329-4721-97AA-01C89FCCD32B

Q28036747-3E789DE6-BEDF-4461-BF22-98AA40371831

Q28036747-4D50B88C-473A-431C-9620-1C2ACE5B2C9E

Q28036747-52F6E5E3-727F-4F99-BB14-3E1CD52341F1

Q28036747-6008D239-7321-4902-BF92-8B7D90852C27

Q28036747-63B29BE7-217B-4CD9-BE3D-0AFCB5D1D8B5

Q28036747-6F231064-5E54-46AD-87E3-E09507F85EAB

Q28036747-87BAB7DA-E505-40F0-9528-7DDE6B3FF405

P304

Q28036747-B90DB67F-CB92-4F5E-842D-88792DAA87C2

P31

Q28036747-99E2A61A-287C-4B5F-A15C-DA1BA406B915

P3181

Q28036747-D7A10F60-A7D3-4D4F-A963-667F623E6139

P356

Q28036747-0498A7A6-3B7A-4E60-8D84-36E30D532AD3

P407

Q28036747-7429002C-9454-4B1B-A226-97CC0EEC3E0C

P433

Q28036747-42EA81A4-B380-45D9-B070-4765AB147F89

P478

Q28036747-AFE30A9C-587D-4455-B105-32C473A76705

P50

Q28036747-D345F1B3-B647-4EC3-8B46-317068CBA961

P577

Q28036747-7BFCAF88-F584-44C6-85FA-237C89973531

P698

Q28036747-80FA785C-A9CE-4F04-8076-823CDE98B3D5

P921

Q28036747-3DEE3B9F-1B46-475A-9F5B-D9B8ABD4956F

Q28036747-96BD965E-77EA-44F8-B96E-B541BABE54E7

P3181

P356

S0140-6736(00)02034-1

P1433

P1476

Irinotecan combined with fluor ...... a multicentre randomised trial

@en

P2093

AD Roth

http://www.w3.org/2001/XMLSchema#string

G Gruia

http://www.w3.org/2001/XMLSchema#string

J Carmichael

http://www.w3.org/2001/XMLSchema#string

JY Douillard

http://www.w3.org/2001/XMLSchema#string

L Awad

http://www.w3.org/2001/XMLSchema#string

M Alakl

http://www.w3.org/2001/XMLSchema#string

M Navarro

http://www.w3.org/2001/XMLSchema#string

P Jandik

http://www.w3.org/2001/XMLSchema#string

P Karasek

http://www.w3.org/2001/XMLSchema#string

P Rougier

http://www.w3.org/2001/XMLSchema#string

P304

1041-1047

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1342646

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/S0140-6736(00)02034-1

http://www.w3.org/2001/XMLSchema#string

P407

P433

9209

http://www.w3.org/2001/XMLSchema#string

P478

355

http://www.w3.org/2001/XMLSchema#string

P50

David Cunningham

P577

2000-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10744089

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

multicenter trial